{{Rsnum
|rsid=4986774
|geno1=(-;-)
|geno2=(-;A)
|geno3=(A;A)
|Orientation=minus
|Chromosome=22
|position=42524244
|Gene=CYP2D6
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
}}{{PharmGKB
|RSID=rs4986774
|Name_s=CYP2D6:2549 del A, part of CYP2D6*3
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19037197; Web Resource:http://preview.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp
|Annotation=This variant is part of the CYP2D6*3 PM haplotype. Plasma concentrations of metoprolol were shown to be were 4.9-fold higher in the PMs, with greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs.
|Drugs=metoprolol
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162372820
}}

{{PharmGKB
|RSID=rs4986774
|Name_s=CYP2D6*3; CYP2D6:2549 del A
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp#ImportantVariantInformationforCYP2D6-666
|Annotation=Causes a frameshift mutation that results in a truncated, non-functional protein and is the diagnostic SNP for the CYP2D6*3 haplotype.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145186
}}